ipamorelin 5gm reconstitute CJC-1295 Blend 5MG Ipamorelin/CJC-1295 (No DAC) 5/5MG -

Research reference only

Intramuscular results in slightly quicker absorption but no meaningful difference in total GH release

Use With Caution In Research Models Involving: Diabetes or impaired glucose regulation Insulin resistance or metabolic syndrome Cardiovascular disease or uncontrolled hypertension Fluid-retention susceptibility or fluid-balancerelated conditions Hormonal or endocrine disorders Sleep apnea or significant respiratory disorders Chronic migraines or neurological sensitivity Kidney or liver impairment Avoid or Carefully Evaluate in Research Models With: Active or suspected malignancies History of growth-sensitive tumors Severe uncontrolled endocrine disorders Severe uncontrolled cardiovascular disease Pregnancy or breastfeeding contexts Known hypersensitivity to peptide compounds Additional Research Considerations Because Ipamorelin may increase endogenous growth hormone and downstream IGF-1 activity, research involving abnormal cellular proliferation, tumor-growth pathways, or uncontrolled metabolic disease should be approached with particular caution

This effect is usually mild and not consistent, but it can matter if you are sensitive to stress hormones